Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deniz Can Guven

Showing results (1-10 of 134) with videos related to

Pageof 14
Sort By:
Clinical Nutrition ESPEN|August 24, 2024
Prognostic impact of myosteatosis on survival with immune checkpoint inhibitors: A systematic review and meta-analysisTaha Koray Sahin, Deniz Can Guven
Breast Cancer Research and Treatment|January 19, 2024
The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors: a systematic review and meta-analysisDeniz Can Guven, Taha Koray Sahin
Cureus|September 15, 2022
Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case ReportHakan Taban, Deniz Can Guven, Saadettin Kılıçkap
Expert Review of Anticancer Therapy|March 13, 2025
Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitorsTaha Koray Sahin, Sercan Aksoy, Deniz Can Guven
Cancers|January 11, 2024
The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung CancerDeniz Can Guven, Taha Koray Sahin, Saadettin Kilickap
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 16, 2022
Infectious complications of cyclin-dependent kinases 4 and 6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer: a systematic review and meta-analysisOnur Bas, Enes Erul, Deniz Can Guven, et al.
Critical Reviews in Oncology/Hematology|June 17, 2025
IGF-1R inhibitors in cancer: A review of available evidence and future outlookDeniz Can Guven, Jibran Ahmed, Bettzy Stephen, et al.
Cureus|July 19, 2021
Radiation Recall Dermatitis in Patients Treated With Immune Checkpoint Inhibitors: A Case Report and Literature ReviewEcem Yigit, Deniz Can Guven, Sercan Aksoy, et al.
Future Oncology (London, England)|February 27, 2020
Gut microbiota and cancer immunotherapy: prognostic and therapeutic implicationsDeniz Can Guven, Burak Yasin Aktas, Cem Simsek, et al.
Biomarkers in Medicine|October 16, 2020
Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectivesDeniz Can Guven, Taha K Sahin, Omer Dizdar, et al.
Pageof 14

Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
Clinical Nutrition ESPEN|August 24, 2024
Prognostic impact of myosteatosis on survival with immune checkpoint inhibitors: A systematic review and meta-analysisTaha Koray Sahin, Deniz Can Guven
Breast Cancer Research and Treatment|January 19, 2024
The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors: a systematic review and meta-analysisDeniz Can Guven, Taha Koray Sahin
Cureus|September 15, 2022
Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case ReportHakan Taban, Deniz Can Guven, Saadettin Kılıçkap
Expert Review of Anticancer Therapy|March 13, 2025
Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitorsTaha Koray Sahin, Sercan Aksoy, Deniz Can Guven
Cancers|January 11, 2024
The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung CancerDeniz Can Guven, Taha Koray Sahin, Saadettin Kilickap
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 16, 2022
Infectious complications of cyclin-dependent kinases 4 and 6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer: a systematic review and meta-analysisOnur Bas, Enes Erul, Deniz Can Guven, et al.
Critical Reviews in Oncology/Hematology|June 17, 2025
IGF-1R inhibitors in cancer: A review of available evidence and future outlookDeniz Can Guven, Jibran Ahmed, Bettzy Stephen, et al.
Cureus|July 19, 2021
Radiation Recall Dermatitis in Patients Treated With Immune Checkpoint Inhibitors: A Case Report and Literature ReviewEcem Yigit, Deniz Can Guven, Sercan Aksoy, et al.
Future Oncology (London, England)|February 27, 2020
Gut microbiota and cancer immunotherapy: prognostic and therapeutic implicationsDeniz Can Guven, Burak Yasin Aktas, Cem Simsek, et al.
Biomarkers in Medicine|October 16, 2020
Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectivesDeniz Can Guven, Taha K Sahin, Omer Dizdar, et al.
Pageof 14